Denali Therapeutics, Inc. (DNLI)
24.20
-0.72
(-2.89%)
USD |
NASDAQ |
Aug 24, 16:00
23.73
-0.47
(-1.94%)
After-Hours: 20:00
Denali Therapeutics Total Assets (Quarterly) : 1.158B for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.158B |
| March 31, 2026 | 1.266B |
| December 31, 2025 | 1.145B |
| September 30, 2025 | 1.056B |
| June 30, 2025 | 1.166B |
| March 31, 2025 | 1.271B |
| December 31, 2024 | 1.374B |
| September 30, 2024 | 1.454B |
| June 30, 2024 | 1.503B |
| March 31, 2024 | 1.581B |
| December 31, 2023 | 1.154B |
| September 30, 2023 | 1.237B |
| June 30, 2023 | 1.306B |
| March 31, 2023 | 1.409B |
| December 31, 2022 | 1.460B |
| September 30, 2022 | 1.228B |
| June 30, 2022 | 1.292B |
| March 31, 2022 | 1.321B |
| December 31, 2021 | 1.404B |
| September 30, 2021 | 1.450B |
| Date | Value |
|---|---|
| June 30, 2021 | 1.510B |
| March 31, 2021 | 1.548B |
| December 31, 2020 | 1.604B |
| September 30, 2020 | 1.070B |
| June 30, 2020 | 647.34M |
| March 31, 2020 | 695.86M |
| December 31, 2019 | 553.23M |
| September 30, 2019 | 602.98M |
| June 30, 2019 | 637.60M |
| March 31, 2019 | 676.60M |
| December 31, 2018 | 661.98M |
| September 30, 2018 | 544.48M |
| June 30, 2018 | 572.06M |
| March 31, 2018 | 613.95M |
| December 31, 2017 | 486.72M |
| September 30, 2017 | 210.31M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 271.07M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Biogen, Inc. | 32.09B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.189B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 322.78M |
| Shareholders Equity (Quarterly) | 835.18M |
| Debt to Equity Ratio | 0.0451 |
| Current Ratio | 8.369 |
| Net Debt Paydown Yield | 0.05% |